From lab to bedside: emerging clinical applications of thymosin α1-Reference-Cited by-同舟云学术

From lab to bedside: emerging clinical applications of thymosin α1

Published:2009-04-24 Issue:5 Volume:9 Page:593-608
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Goldstein Allan L¹,Goldstein Adam L²

Affiliation:

1. The George Washington University School of Medicine and Health Sciences, Department of Biochemistry & Molecular Biology, 2300 I St., N.W., Room 438, Washington, DC, USA ; ;

2. Medical School for International Health at Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Publisher

Informa Healthcare

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1517/14712590902911412

Reference114 articles.

1. Biological response modifiers and infectious diseases: Actual and potential therapeutic agents

2. Combination therapy with BRMs in cancer and infectious diseases

3. Biological response modifiers in the management of rheumatoid arthritis

4. Thymosins: chemistry and biological properties in health and disease

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenotypic drug discovery: a case for thymosin alpha-1;Frontiers in Medicine;2024-06-06

2. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies;Frontiers in Endocrinology;2023-07-11

3. Immunoregulatory actions of calf thymus extract (TFX®) in vitro in relation to its effect on expression of mitogen activated protein kinases;International Immunopharmacology;2023-05

4. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications;International Immunopharmacology;2023-04

5. Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis;Chinese Medical Journal;2021-11-03